#ASCO24 #leusm Muffly: so much effort has been put into finding HLA matched donors historically, but the ACCESS study shows HLA matching essentially irrelevant using PTCy with such phenomenal outcomes! Everyone has a donor. Javier Bolaños Meade, MD: #ptcyrules (but still needs optimization)

Fresh off the press🎉🎉Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.120…

This free review on TEG is pretty solid.

I will save these images for when I am forced to interpret this study.

Viscoelastic testing: an illustrated review of technology and clinical applications - Research and Practice in Thrombosis and Haemostasis rpthjournal.org/article/S2475-…

Lupus Anticoagulant (LA) simplified!

3 step coagulation assay detects antiphospholipid antibodies

1. PTT/DRVVT⬆️?
Yes = go to 2
No = No LA

2. Does PTT correct after 1:1 mix?
No = go to 3
Yes = No LA

3. Does ⬆️PTT correct with addition of phospholipids? Yes = LA!
No = No LA

Happy to attend the advanced #CRTILA . A truly enriching experience 🩸. Thanks #ASH , faculties and peers for all the support. Ready to move forward 🔎

The future of clinical research in Latin America is safe in the hands of these bright minds ASH #CRTILA24

Now I can finally leave the trenches and fulfill my dream of becoming…. an administrator👨‍💼 #PeterPrinciple

CRTI - LA 2024
Medellin Colombia

Collaborating with trainees from Latinamerica and great faculty from the region and US to promote research and networking.

ASH @IUHIBA

Trainees and faculty hard at work solving global issues in #BMTsm #CRTILA24 ASH

Empezando el curso en Medellín #ASH #CRTILA

My comments at the FDA ODAC on MRD as an accelerated approval endpoint in Myeloma

Safety is the big reason this is a bad decision

Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for #AML #leusm |British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.11…

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial - thelancet.com/journals/lanha… #leusm #AML

THSNA 2024: THSNA. So thankful and happy for this great experience; giving a session, my first time being chair and the young investigator award.

Lymphoma Classification

Any suggestions/critiques?

Aaron Goodman - “Papa Heme” 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM David Russler-Germain, MD/PhD Eddie Cliff Charles Milrod, MD

Let alone treating MRD resurgence, there are many patients with myeloma undergoing biochemical relapses who can be safely observed.

Obviously, these patients should be selected wisely, but not every biochemical relapse needs immediate/aggressive treatment.

#mmsm

Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. pubmed.ncbi.nlm.nih.gov/38450850/ Five tables, 7 figures and 13 years of work summarized! #CMML #ASXL1 Mayo Clinic Comprehensive Cancer Center The Leukemia & Lymphoma Society AA&MDSIF

I really love this „less-is-more“ studies. Olanazapine is still a highly effective antiemetic drug at a much lower dose (2.5 mg). Will change my practice from tomorrow.

thelancet.com/journals/lanon…

How did we lose our tail? A simple question.. but it wasn't really asked before! We discovered a plausible scenario for the genetic mechanism that led to tail loss. Amazing that such a big change may have been caused by such a small genetic event. nature.com/articles/s4158… Bo Xia

📢📢 𝐍𝐄𝐖 𝐓𝐇𝐑𝐄𝐀𝐃 🧵

This is for everyone who uses 𝙘𝙮𝙘𝙡𝙤𝙨𝙥𝙤𝙧𝙞𝙣𝙚, so I'm guessing a lot of people would read this short thread !

It's every transplanter's friend; kidney/🫀/ liver/ BMT 💪

Follow along to learn more 👇

1/20

#MedTwitter

Cyclosporine A on day 0 can prevent CRS severity in patients undergoing outpatient PBSC Haplo, in this Mexican randomized Phase 2 trial by Perla Colunga

No impact on hard outcomes, hospitalization or LoS which had a median of 3.5 days!

Beat that! #Tandem24 #MonterreyPower